Telix Pharmaceuticals Limited

Company Profile

Telix Pharmaceuticals Limited had its IPO on under the ticker symbol TLPPF.

The company operates in the Healthcare sector and Biotechnology industry. Telix Pharmaceuticals Limited has a staff strength of 234 employees.

Stock update

Shares of Telix Pharmaceuticals Limited opened at $7.28 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $7.28 - $7.28, and closed at $7.28.

This is a -0.41% slip from the previous day's closing price.

A total volume of 300 shares were traded at the close of the day’s session.

In the last one week, shares of Telix Pharmaceuticals Limited have increased by +0.28%.

Telix Pharmaceuticals Limited's Key Ratios

Telix Pharmaceuticals Limited has a market cap of $2.24 billion, indicating a price to book ratio of 21.1586 and a price to sales ratio of 52.2133.

In the last 12-months Telix Pharmaceuticals Limited’s revenue was $356.88 million with a gross profit of $98.54 million and an EBITDA of $26.17 million. The EBITDA ratio measures Telix Pharmaceuticals Limited's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Telix Pharmaceuticals Limited’s operating margin was 6.12% while its return on assets stood at 5.18% with a return of equity of -52.36%.

In Q2, Telix Pharmaceuticals Limited’s quarterly earnings growth was a positive 0% while revenue growth was a positive 818.3%.

Telix Pharmaceuticals Limited’s PE and PEG Ratio

Forward PE

21.5517

Trailing PE

0

PEG

Its diluted EPS in the last 12-months stands at $-0.09 per share while it has a forward price to earnings multiple of 21.5517 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Telix Pharmaceuticals Limited’s profitability.

Telix Pharmaceuticals Limited stock is trading at a EV to sales ratio of 54.669 and a EV to EBITDA ratio of -12.8918. Its price to sales ratio in the trailing 12-months stood at 52.2133.

Telix Pharmaceuticals Limited stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$255.35 million

Total Liabilities

$85.56 million

Operating Cash Flow

$-5667500.00

Capital Expenditure

$1.19 million

Dividend Payout Ratio

0%

Telix Pharmaceuticals Limited ended 2024 with $255.35 million in total assets and $0 in total liabilities. Its intangible assets were valued at $255.35 million while shareholder equity stood at $80.01 million.

Telix Pharmaceuticals Limited ended 2024 with $0 in deferred long-term liabilities, $85.56 million in other current liabilities, 370972000.00 in common stock, $-272815000.00 in retained earnings and $5.52 million in goodwill. Its cash balance stood at $116.33 million and cash and short-term investments were $116.33 million. The company’s total short-term debt was $641,000 while long-term debt stood at $3.31 million.

Telix Pharmaceuticals Limited’s total current assets stands at $173.23 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $39.35 million compared to accounts payable of $16.81 million and inventory worth $8.48 million.

In 2024, Telix Pharmaceuticals Limited's operating cash flow was $-5667500.00 while its capital expenditure stood at $1.19 million.

Comparatively, Telix Pharmaceuticals Limited paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$7.28

52-Week High

$8.53

52-Week Low

$2.865

Analyst Target Price

$

Telix Pharmaceuticals Limited stock is currently trading at $7.28 per share. It touched a 52-week high of $8.53 and a 52-week low of $8.53. Analysts tracking the stock have a 12-month average target price of $.

Its 50-day moving average was $7.13 and 200-day moving average was $5.99 The short ratio stood at 0 indicating a short percent outstanding of 0%.

Around 2749% of the company’s stock are held by insiders while 1352% are held by institutions.